Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2327-2335

  Bachet, J B ^a,b,c,d   Marechal R ^d   Demetter, P ^d   Bonnetain, F ^e   Couvelard, A ^f   Svrcek, M ^a,g   Bardier dupas, A ^a,c   Hammel, P ^f   Sauvanet, A ^f   Louvet, C ^a,g,h   Paye, F ^a,g   Rougier, P ^b,i   Penna, C ^b,j   Vaillant, J C ^a,c   Andre T ^a,c   Closset, J ^d   Salmon, I ^d   Emile, J F ^b,j   Van laethem, J L ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ERASME HOSPITAL   (Belgium)

^e Biostatistic and Quality of Life Unit Georges François Leclerc Center   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h INSTITUT MUTUALISTE MONTSOURIS   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

Adjuvant chemotherapy; CXCR4; LKB1; Pancreatic adenocarcinoma; Smad4; Type II TGF receptor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CISPLATIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PROTEIN KINASE LKB1; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; TISSUE MICROARRAY; TREND STUDY;

EID: 84863542976     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr617     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin, 2009; 59: 225-249.
2. Carpelan-Holmström M, Nordling S, Pukkala E et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut, 2005; 54: 385-387.
3. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 2007; 297: 267-277.
4. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004; 350: 1200-1210.
5. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA, 2010; 304: 1073-1081.
6. Jamieson NB, Carter CR, McKay CJ, Oien KA Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res, 2011; 17: 3316-3331.
7. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor β in human disease. N Engl J Med, 2000; 342: 1350-1358.
8. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008; 321: 1801-1806.
9. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 1996; 271: 350-353.
10. Wagner M, Kleeff J, Friess H et al. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas, 1999; 19: 370-376.
11. Blackford A, Serrano OK, Wolfgang CL et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res, 2009; 15: 4674-4679.
12. Tascilar M, Skinner HG, Rosty C et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res, 2001; 7: 4115-4121.
13. Biankin AV, Morey AL, Lee CS et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol, 2002; 20: 4531-4542.
14. Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol, 2007; 25: 319-325.
15. Biankin AV, Kench JG, Colvin EK et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 2009; 137: 558-568.
16. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol, 2009; 27: 1806-1813.
17. Crane CH, Varadhachary GR, Yordy JS et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol, 2011; 29: 3037-3043.
18. Saur D, Seidler B, Schneider G et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology, 2005; 129: 1237-1250.
19. Maréchal R, Demetter P, Nagy N et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer, 2009; 100: 1444-1451.
20. DiPersio JF, Micallef IN, Stiff PJ et al. Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009; 27: 4767-4773.
21. Shaw RJ, Kosmatka M, Bardeesy N et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A, 2004; 101: 3329-3335.
22. Morton JP, Jamieson NB, Karim SA et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 2010; 139: 586-597.
23. Gonzalez-Angulo AM, Meric-Bernstam F Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res, 2010; 16: 1695-1700.
24. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol, 2005; 2: 416-422.
25. Mesker WE, Liefers GJ, Junggeburt JMC et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer. Cell Oncol, 2009; 31: 169-178.
26. Concato J, Peduzzii P, Holford TR, Feinstein AR Importance of events per independent variable in proportional hazards analysis. Background, Goals, and General Strategy. J Clin Epidemiol, 1995; 48: 1495-1501.
27. Harrell FE, Lee KL, Mark DB Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996; 15: 361-387.
28. Soria JC, Blay JY, Spano JP et al. Added value of molecular targeted agents in oncology. Ann Oncol, 2011; 22: 1703-1716.
29. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008; 26: 374-379.
30. Bachet JB, Mitry E, Lièvre A et al. Are second- and third-line chemotherapy beneficial in patients with metastatic pancreatic adenocarcinoma?. Gastroenterol Clin Biol, 2009; 33: 1036-1044.
31. Proudfoot AE Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol, 2002; 2: 106-115.
32. Marchesi F, Monti P, Leone BE et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res, 2004; 64: 8420-8427.
33. Thomas RM, Kim J, Revelo-Penafiel MP et al. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut, 2008; 57: 1555-1560.
34. Teicher BA, Fricker SP CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res, 2010; 16: 2927-2931.
35. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007; 1: 313-323.
36. Bierie B, Moses HL Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer, 2006; 6: 506-520.
37. Zavadil J, Böttinger EP TGF-beta and epithelial-to-mesenchymal transitions. Oncogene, 2005; 24: 5764-5774.
38. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol, 2000; 156: 37-43.
39. Bardeesy N, Cheng KH, Berger JH et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev, 2006; 20: 3130-3146.
40. Izeradjene K, Combs C, Best M et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell, 2007; 11: 229-243.
41. Katoh M, Katoh M Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFβ, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol, 2010; 36: 415-420.
42. Mandrekar SJ, Sargent DJ Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol, 2009; 27: 4027-4034.
43. Farrell JJ, Elsaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology, 2009; 136: 187-195.
44. Maréchal R, Mackey JR, Lai R et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res, 2009; 15: 2913-2919.